Compare Novavax Inc (NVAX) vs SP Funds S&P 500 Sharia Industry Exclusions ETF (SPUS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novavax Inc vs SP Funds S&P 500 Sharia Industry Exclusions ETF — how do they compare? Novavax Inc trades at $12.61 (market cap $1.82B), while SP Funds S&P 500 Sharia Industry Exclusions ETF trades at $60.71 (market cap $3.39B). The key difference: SP Funds S&P 500 Sharia Industry Exclusions ETF is the larger of the two by market cap, and SP Funds S&P 500 Sharia Industry Exclusions ETF is more actively traded (349,184 versus 6,198,505). Which is the better fit depends on your goals — on Pluang, investors hold Novavax Inc for 59 Days and SP Funds S&P 500 Sharia Industry Exclusions ETF for 64 Days on average.
| NVAX | SPUS | |
|---|---|---|
Market Cap | $1.82B | $3.39B |
Volume | 6,198,505 | 349,184 |
Sector | Health | Broad Market / Factor |
52-Week High | $12.56 | $61.15 |
52-Week Low | $6.22 | $46.65 |
Typical Hold Time | 59 Days | 64 Days |
Enterprise Value | $1.39B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novavax (NVAX) trades at $12.41, up 10.61% today, with strong technical momentum and bullish moving average signals. The company shows mixed fundamentals with a low P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent earnings beats and FDA approvals for updated COVID-19 vaccines provide near-term catalysts.
Investment outlook remains speculative with significant execution risks despite analyst optimism (74% buy ratings). The company's pivot to Matrix-M adjuvant licensing and partnership model offers growth potential, but negative cash flow and high debt levels pose substantial financial risk. Stock appears undervalued on some metrics but requires careful risk management.
SPUS (SP Funds S&P 500 Sharia Industry Exclusions ETF) trades at $61.07, down 0.13% with a bullish technical signal from moving averages but bearish oscillators. The ETF shows consistent dividend payments of $0.03 monthly through mid-2026. Short interest surged 174.5% to 257,142 shares in September 2026, indicating growing bearish sentiment among some investors despite the overall technical strength.
The ETF's outlook remains mixed with strong technical momentum countered by elevated short interest and overbought RSI levels. Investment opportunity lies in Sharia-compliant S&P 500 exposure, while risks include concentrated short positioning and potential mean reversion from current technical extremes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novavax Inc
Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →About SP Funds S&P 500 Sharia Industry Exclusions ETF
SPUS tracks a market-cap weighted index of S&P 500 stocks that adhere to Sharia law. It screens out companies involved in non-compliant business activities such as alcohol, tobacco, gambling, and conventional finance, as well as excluding sectors like Aerospace & Defense, and Data Processing. By focusing on low-leverage stocks, SPUS provides investors with a value-conscious, ethically-aligned exposure to a diversified portfolio of large-cap U.S. equities.
Read more on SPUS →
